DelMar Pharmaceuticals (NASDAQ:DMPI) Receives “Buy” Rating from Maxim Group

Maxim Group reiterated their buy rating on shares of DelMar Pharmaceuticals (NASDAQ:DMPI) in a report published on Friday, reports.

Separately, Zacks Investment Research raised shares of DelMar Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 29th.

DMPI traded down $0.09 on Friday, reaching $0.66. 14,785 shares of the company traded hands, compared to its average volume of 726,679. The stock’s 50 day moving average price is $0.58 and its 200-day moving average price is $1.20. DelMar Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $6.80. The company has a market cap of $2.04 million, a price-to-earnings ratio of -0.21 and a beta of 1.30.

DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its quarterly earnings data on Tuesday, September 10th. The company reported ($0.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.59). On average, sell-side analysts anticipate that DelMar Pharmaceuticals will post -1.2 earnings per share for the current year.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.

See Also: What is the Bid-Ask Spread?

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit